---
id: xaira-therapeutics
slug: xaira-therapeutics
entity_type: commercial
status: operational
data_completeness: high
last_researched: 2025-01-27
researcher: AI Assistant
version: 1.1
name: Xaira Therapeutics
description: Integrated biotechnology company using AI to transform drug discovery and development, combining advanced machine learning research, extensive data generation, and robust therapeutic product development
mission: "To reimagine drug discovery and development by fully leveraging modern AI technologies. Xaira combines three key elements: (1) Advanced AI research - developing fundamental computational methods and applying them to biological discovery, molecule design, and clinical development, (2) Extensive data generation - creating comprehensive multi-dimensional datasets spanning biology at all levels from molecules to whole organisms, (3) Robust therapeutic product development - applying design capabilities to previously 'undruggable' targets to create differentiated therapeutics."
entity_data:
  focus: Integrated biotechnology company using AI to transform drug discovery and development, combining advanced machine learning research, extensive data generation, and robust therapeutic product development
  status: operational
  founded: 2023
  website: "https://www.xaira.com"
  industry: Biotechnology
  launched: 2024-04
  employees:
  as_of: 2024
  current: Not disclosed
  legal_name: Xaira Therapeutics
  headquarters:
  city: South San Francisco
  state: California
  address: 700 Gateway Blvd, 4th Floor, South San Francisco, CA 94080
  country: USA
  additional_offices:
  -
  city: Seattle
  state: Washington
  country: USA
  purpose: Research and development
  -
  city: London
  country: United Kingdom
  purpose: Research and development
taxonomy:
  geography: USA
  ai_approach:
  - Generative AI
  ai_technology:
  - Generative AI
  - Diffusion Models
  primary_focus:
  - AI-Driven Drug Discovery
  - Protein Design & Engineering
  aging_approach:
  - Molecule Design
  target_biology:
  - Cancer/Oncology
  - General Aging/Longevity
  ai_architecture:
  - Diffusion Models
  ai_specialization: []
  development_stage: Research / Preclinical
  organization_type: commercial
  organization_subtype: operational
  therapeutic_modality:
  - Therapeutic Proteins
organizations:
  -
    name: Two Sigma Ventures
    role: partner
    org_type: company
    status: operational
    role_description: Series A investor
  -
    name: Lux Capital
    role: partner
    org_type: company
    status: operational
    role_description: Series A investor
  -
    name: SV Angel
    role: partner
    org_type: company
    status: operational
    role_description: Series A investor
  -
    name: Xaira Therapeutics
    role: primary
    org_type: company
    legal_name: Xaira Therapeutics
    founded: 2023
    website: "https://www.xaira.com"
    status: operational
    role_description: Primary organization - Xaira Therapeutics
  -
    name: Foresite Capital
    role: partner
    org_type: company
    status: operational
    role_description: Series A investor
  -
    name: ARCH Venture Partners
    role: partner
    org_type: company
    status: operational
    role_description: Co-incubator and lead investor
  -
    name: Oracle Cloud Infrastructure
    role: partner
    org_type: company
    status: operational
    role_description: Strategic partner providing cloud infrastructure for AI-driven drug discovery
  -
    name: University of Washington - Institute for Protein Design
    role: partner
    org_type: institution
    website: "https://www.ipd.uw.edu"
    status: operational
    role_description: "Research collaboration partner - computational core based on David Baker's work"
  -
    name: Menlo Ventures
    role: partner
    org_type: company
    status: operational
    role_description: Series A investor
  -
    name: Parker Institute for Cancer Immunotherapy
    role: partner
    org_type: institution
    status: operational
    role_description: Series A investor
  -
    name: NEA
    role: partner
    org_type: company
    status: operational
    role_description: Series A investor
  -
    name: Lightspeed Venture Partners
    role: partner
    org_type: company
    status: operational
    role_description: Series A investor
  -
    name: Foresite Labs
    role: partner
    org_type: company
    status: operational
    role_description: Co-incubator and lead investor
  -
    name: F-Prime Capital
    role: partner
    org_type: company
    status: operational
    role_description: Series A investor
  -
    name: Sequoia Capital
    role: partner
    org_type: company
    status: operational
    role_description: Series A investor
products:
  -
    name: RFantibody
    type: ai_model
    status: In Development/Use
    development_stage: In Development/Use
  -
    name: X-Atlas/Orion
    type: platform
    status: Released
    development_stage: Released
  -
    name: RFantibody
    type: ai_model
    status: In Development/Use
    development_stage: In Development/Use
  -
    name: RFdiffusion
    type: ai_model
    status: In Development/Use
    development_stage: In Development/Use
  -
    name: X-Atlas/Orion
    type: platform
    status: Released
    development_stage: Released
  -
    name: RFdiffusion
    type: ai_model
    status: In Development/Use
    development_stage: In Development/Use
links:
  -
    url: "https://www.intelligence360.news/xaira-therapeutics-to-expand-into-73075-square-feet-of-space-in-san-francisco-california/"
    type: news_article
    title: Xaira Therapeutics to Expand into 73,075 Square Feet of Space in San Francisco, California
  -
    url: "https://www.xaira.com/our-approach"
    type: website
    title: Xaira Therapeutics - Our Approach
  -
    url: "https://www.businesswire.com/news/home/20241211004372/en/Xaira-Therapeutics-Announces-the-Appointment-of-Dr.-Paulo-Fontoura-as-Chief-Medical-Officer-and-Dr.-Hetu-Kamisetty-as-Chief-Technology-Officer"
    type: press_release
    title: Xaira Therapeutics Announces the Appointment of Dr. Paulo Fontoura as Chief Medical Officer and Dr. Hetu Kamisetty as Chief Technology Officer
  -
    url: "https://www.rdworldonline.com/xaira-therapeutics-releases-8-million-cell-dataset-touting-it-as-the-largest-public-resource-for-ai-drug-discovery/"
    type: news_article
    title: Xaira Therapeutics Releases 8 Million Cell Dataset, Touting It as the Largest Public Resource for AI Drug Discovery
  -
    url: "https://www.biopharmatrend.com/news/xaira-therapeutics-appoints-biotech-exec-behind-belharra-and-ambys-as-president-and-coo-to-scale-ai-driven-drug-discovery-platform-1312/"
    type: news_article
    title: Xaira Therapeutics Appoints Biotech Exec Behind Belharra and Ambys as President and COO to Scale AI-Driven Drug Discovery Platform
  -
    url: "https://www.xaira.com/work-with-us"
    type: website
    title: Xaira Therapeutics - Work With Us
  -
    url: "https://www.businesswire.com/news/home/20240423707240/en/"
    type: press_release
    title: Xaira Therapeutics Launches with Over $1 Billion in Funding to Reimagine Drug Discovery and Development
  -
    url: "https://readmagazine.com/industries/biotechnology/xaira-therapeutics-appoints-dr-debbie-law-as-cso/"
    type: news_article
    title: Xaira Therapeutics Appoints Dr. Debbie Law as CSO
  -
    url: "https://techcrunch.com/2024/04/24/xaira-an-ai-drug-discovery-startup-launches-with-a-massive-1b-says-its-ready-to-start-developing-drugs/"
    type: news_article
    title: "Xaira, an AI drug discovery startup, launches with a massive $1B, says it's ready to start developing drugs"
---

# Xaira Therapeutics

## Description

Integrated biotechnology company using AI to transform drug discovery and development, combining advanced machine learning research, extensive data generation, and robust therapeutic product development

## Mission

To reimagine drug discovery and development by fully leveraging modern AI technologies. Xaira combines three key elements: (1) Advanced AI research - developing fundamental computational methods and applying them to biological discovery, molecule design, and clinical development, (2) Extensive data generation - creating comprehensive multi-dimensional datasets spanning biology at all levels from molecules to whole organisms, (3) Robust therapeutic product development - applying design capabilities to previously 'undruggable' targets to create differentiated therapeutics.

## Company Information

**Legal Name**: Xaira Therapeutics
**Founded**: 2023
**Industry**: Biotechnology
**Employees**: {"as_of":"2024","current":"Not disclosed"}
**Focus**: Integrated biotechnology company using AI to transform drug discovery and development, combining advanced machine learning research, extensive data generation, and robust therapeutic product development
**Website**: https://www.xaira.com

## Lessons Learned

### Achievements

- Secured over $1 billion in Series A funding, one of the largest biotech funding rounds
- Assembled world-class leadership team with experience from Stanford, Genentech, Roche, Bristol Myers Squibb, Janssen, Merck
- Released X-Atlas/Orion, world's largest public Perturb-seq dataset (8 million cells)
- Established strategic partnership with Oracle Cloud Infrastructure
- Based on Nobel Prize-winning research by co-founder David Baker
- Successfully relocated to new headquarters in South San Francisco

### Challenges

- Integrating advanced AI research with extensive data generation and therapeutic product development
- Targeting previously undruggable targets requires novel computational approaches
- Scaling AI-driven drug discovery platform requires significant infrastructure and expertise
- Balancing research innovation with clinical development timelines

### Impact on Field

Xaira Therapeutics represents a major advancement in AI-driven drug discovery, combining Nobel Prize-winning protein design research with extensive data generation and therapeutic development capabilities. The company's approach of targeting previously undruggable targets using AI-designed proteins and antibodies has significant potential for longevity research, as many aging-related targets have been difficult to address with traditional small molecules. The release of the X-Atlas/Orion dataset (8 million cells) provides a valuable public resource for the entire AI drug discovery community. With over $1 billion in funding and a world-class team, Xaira is well-positioned to accelerate the development of novel therapeutics targeting aging mechanisms and age-related diseases.

## Organizations

### Two Sigma Ventures
**Role in Project**: partner
**Role Description**: Series A investor
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm
**Focus**: Venture capital, data science and technology investment

### Lux Capital
**Role in Project**: partner
**Role Description**: Series A investor
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm focused on emerging science and technology
**Focus**: Venture capital, science and technology investment

### SV Angel
**Role in Project**: partner
**Role Description**: Series A investor
**Organization Type**: company
**Status**: operational
**Description**: Early-stage venture capital firm
**Focus**: Venture capital, early-stage investment

### Xaira Therapeutics
**Role in Project**: primary
**Role Description**: Primary organization - Xaira Therapeutics
**Organization Type**: company
**Status**: operational
**Founded**: 2023
**Website**: https://www.xaira.com
**Description**: Integrated biotechnology company using AI to transform drug discovery and development, combining advanced machine learning research, extensive data generation, and robust therapeutic product development
**Focus**: Integrated biotechnology company using AI to transform drug discovery and development, combining advanced machine learning research, extensive data generation, and robust therapeutic product development

### Foresite Capital
**Role in Project**: partner
**Role Description**: Series A investor
**Organization Type**: company
**Status**: operational
**Description**: Healthcare-focused investment firm
**Focus**: Healthcare investment, biotechnology

### ARCH Venture Partners
**Role in Project**: partner
**Role Description**: Co-incubator and lead investor
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm focused on early-stage life sciences and technology companies
**Focus**: Venture capital, biotechnology investment

### Oracle Cloud Infrastructure
**Role in Project**: partner
**Role Description**: Strategic partner providing cloud infrastructure for AI-driven drug discovery
**Organization Type**: company
**Status**: operational
**Description**: Cloud computing platform providing infrastructure services for AI and drug discovery initiatives
**Focus**: Cloud infrastructure, AI computing, drug discovery platform support

### University of Washington - Institute for Protein Design
**Role in Project**: partner
**Role Description**: Research collaboration partner - computational core based on David Baker's work
**Organization Type**: institution
**Status**: operational
**Website**: https://www.ipd.uw.edu
**Description**: Research institute focused on computational protein design, led by Nobel Prize winner David Baker
**Focus**: Protein design research, RFdiffusion, RFantibody technologies, computational biology

### Menlo Ventures
**Role in Project**: partner
**Role Description**: Series A investor
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm
**Focus**: Venture capital, technology investment

### Parker Institute for Cancer Immunotherapy
**Role in Project**: partner
**Role Description**: Series A investor
**Organization Type**: institution
**Status**: operational
**Description**: Research institute focused on cancer immunotherapy
**Focus**: Cancer immunotherapy research and development

### NEA
**Role in Project**: partner
**Role Description**: Series A investor
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm
**Focus**: Venture capital, technology and healthcare investment

### Lightspeed Venture Partners
**Role in Project**: partner
**Role Description**: Series A investor
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm
**Focus**: Venture capital, technology investment

### Foresite Labs
**Role in Project**: partner
**Role Description**: Co-incubator and lead investor
**Organization Type**: company
**Status**: operational
**Description**: Venture creation firm focused on life sciences innovation
**Focus**: Life sciences innovation, company incubation, strategic guidance

### F-Prime Capital
**Role in Project**: partner
**Role Description**: Series A investor
**Organization Type**: company
**Status**: operational
**Description**: Healthcare and technology investment firm
**Focus**: Healthcare investment, technology

### Sequoia Capital
**Role in Project**: partner
**Role Description**: Series A investor
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm
**Focus**: Venture capital, technology investment

## Locations

### Xaira Therapeutics Headquarters
**Type**: headquarters
**Address**: 700 Gateway Blvd, 4th Floor, South San Francisco, CA 94080
**City**: South San Francisco
**State/Region**: California
**Country**: USA
**Organizations**: Xaira Therapeutics

### Xaira Therapeutics London Office
**Type**: office
**City**: London
**Country**: United Kingdom
**Organizations**: Xaira Therapeutics

### Xaira Therapeutics Seattle Office
**Type**: office
**City**: Seattle
**State/Region**: Washington
**Country**: USA
**Organizations**: Xaira Therapeutics

### University of Washington Campus
**Type**: headquarters
**City**: Seattle
**State/Region**: Washington
**Country**: USA
**Organizations**: University of Washington - Institute for Protein Design

## Products

### RFantibody
**Type**: ai_model
**Status**: In Development/Use
**Development Stage**: In Development/Use
**Role in Project**: primary
**Relationship Description**: Machine learning model for designing new antibodies from scratch
**Description**: Machine learning model for designing new antibodies from scratch. Part of Xaira's computational core enabling creation of therapeutics for previously undruggable targets.
**Mechanism of Action**: Machine learning model for designing new antibodies from scratch. Part of Xaira's computational core enabling creation of therapeutics for previously undruggable targets.
**Target**: Antibody design
**Pathway**: Therapeutic antibody development
**Indications**: [
  {
    "primary": "Novel antibody design for therapeutic applications",
    "secondary": "Targeting previously undruggable targets"
  }
]
**Technical Details**:
```yaml
notes: Core technology for antibody design
foundation: Based on work by David Baker and Institute for Protein Design
architecture: AI model for antibody design
capabilities:
  - Design new antibodies from scratch
  - Target previously undruggable targets
  - Create differentiated therapeutics
regulatory_status: Research tool / Platform
```

### X-Atlas/Orion
**Alternative Names**: X-Atlas, Orion
**Type**: platform
**Status**: Released
**Development Stage**: Released
**Role in Project**: primary
**Relationship Description**: World's largest public Perturb-seq dataset for AI drug discovery
**Description**: Largest public Perturb-seq dataset containing information about 8 million cells. This resource is designed to improve AI models in drug discovery by providing comprehensive multi-dimensional cellular perturbation data spanning biology at all levels.
**Mechanism of Action**: Largest public Perturb-seq dataset containing information about 8 million cells. This resource is designed to improve AI models in drug discovery by providing comprehensive multi-dimensional cellular perturbation data spanning biology at all levels.
**Target**: AI model training and drug discovery
**Pathway**: Cellular biology, drug discovery pipeline
**Indications**: [
  {
    "primary": "AI model training for drug discovery",
    "secondary": "Biological research and therapeutic development"
  }
]
**Technical Details**:
```yaml
size: 8 million cells
notes: "Released in June 2025 as the world's largest public Perturb-seq dataset"
purpose: Support AI models in biology and accelerate drug development
description: Largest public resource for AI drug discovery
launch_date: 2025-06
dataset_type: Perturb-seq
release_date: 2025-06
regulatory_status: Public research resource
```

### RFantibody
**Type**: ai_model
**Status**: In Development/Use
**Development Stage**: In Development/Use
**Role in Project**: primary
**Relationship Description**: Machine learning model for designing new antibodies from scratch
**Description**: Machine learning model for designing new antibodies from scratch. Part of Xaira's computational core enabling creation of therapeutics for previously undruggable targets.
**Mechanism of Action**: Machine learning model for designing new antibodies from scratch. Part of Xaira's computational core enabling creation of therapeutics for previously undruggable targets.
**Target**: Antibody design
**Pathway**: Therapeutic antibody development
**Indications**: [
  {
    "primary": "Novel antibody design for therapeutic applications",
    "secondary": "Targeting previously undruggable targets"
  }
]
**Technical Details**:
```yaml
notes: Core technology for antibody design
foundation: Based on work by David Baker and Institute for Protein Design
architecture: AI model for antibody design
capabilities:
  - Design new antibodies from scratch
  - Target previously undruggable targets
  - Create differentiated therapeutics
regulatory_status: Research tool / Platform
```

### RFdiffusion
**Type**: ai_model
**Status**: In Development/Use
**Development Stage**: In Development/Use
**Role in Project**: primary
**Relationship Description**: Machine learning model for designing new proteins from scratch
**Description**: Machine learning model for designing new proteins from scratch. Part of Xaira's computational core based on fundamental work by co-founder David Baker and his team at the Institute for Protein Design at University of Washington.
**Mechanism of Action**: Machine learning model for designing new proteins from scratch. Part of Xaira's computational core based on fundamental work by co-founder David Baker and his team at the Institute for Protein Design at University of Washington.
**Target**: Protein design
**Pathway**: Therapeutic protein development
**Indications**: [
  {
    "primary": "Novel protein design for therapeutic applications",
    "secondary": "Targeting previously undruggable targets"
  }
]
**Technical Details**:
```yaml
notes: "Core technology based on David Baker's research at University of Washington"
foundation: Based on work by David Baker and Institute for Protein Design
architecture: Diffusion model for protein design
capabilities:
  - Design new proteins from scratch
  - Target previously undruggable targets
  - Create differentiated therapeutics
regulatory_status: Research tool / Platform
```

### X-Atlas/Orion
**Alternative Names**: X-Atlas, Orion
**Type**: platform
**Status**: Released
**Development Stage**: Released
**Role in Project**: primary
**Relationship Description**: World's largest public Perturb-seq dataset for AI drug discovery
**Description**: Largest public Perturb-seq dataset containing information about 8 million cells. This resource is designed to improve AI models in drug discovery by providing comprehensive multi-dimensional cellular perturbation data spanning biology at all levels.
**Mechanism of Action**: Largest public Perturb-seq dataset containing information about 8 million cells. This resource is designed to improve AI models in drug discovery by providing comprehensive multi-dimensional cellular perturbation data spanning biology at all levels.
**Target**: AI model training and drug discovery
**Pathway**: Cellular biology, drug discovery pipeline
**Indications**: [
  {
    "primary": "AI model training for drug discovery",
    "secondary": "Biological research and therapeutic development"
  }
]
**Technical Details**:
```yaml
size: 8 million cells
notes: "Released in June 2025 as the world's largest public Perturb-seq dataset"
purpose: Support AI models in biology and accelerate drug development
description: Largest public resource for AI drug discovery
launch_date: 2025-06
dataset_type: Perturb-seq
release_date: 2025-06
regulatory_status: Public research resource
```

### RFdiffusion
**Type**: ai_model
**Status**: In Development/Use
**Development Stage**: In Development/Use
**Role in Project**: primary
**Relationship Description**: Machine learning model for designing new proteins from scratch
**Description**: Machine learning model for designing new proteins from scratch. Part of Xaira's computational core based on fundamental work by co-founder David Baker and his team at the Institute for Protein Design at University of Washington.
**Mechanism of Action**: Machine learning model for designing new proteins from scratch. Part of Xaira's computational core based on fundamental work by co-founder David Baker and his team at the Institute for Protein Design at University of Washington.
**Target**: Protein design
**Pathway**: Therapeutic protein development
**Indications**: [
  {
    "primary": "Novel protein design for therapeutic applications",
    "secondary": "Targeting previously undruggable targets"
  }
]
**Technical Details**:
```yaml
notes: "Core technology based on David Baker's research at University of Washington"
foundation: Based on work by David Baker and Institute for Protein Design
architecture: Diffusion model for protein design
capabilities:
  - Design new proteins from scratch
  - Target previously undruggable targets
  - Create differentiated therapeutics
regulatory_status: Research tool / Platform
```

## Key People

### Vikram Bajaj
**Participation Type**: founder
**Role in Project**: Co-founder, Director, Interim President
**Participation Period**: 2023-present
**Expertise**: Biotechnology, genomics
**Biography**: Non-executive director of Genomics England

### Hetu Kamisetty
**Participation Type**: founder
**Role in Project**: Co-founder, Chief Technology Officer
**Participation Period**: 2023-present
**Expertise**: AI/ML, protein design, computational methods
**Biography**: Previously worked at Meta and Institute for Protein Design

### Debbie Law
**Participation Type**: leadership
**Role in Project**: Chief Scientific Officer
**Participation Period**: 2024-10-present
**Expertise**: Drug discovery, pharmaceutical R&D
**Biography**: Previously held leadership positions at Bristol Myers Squibb, Janssen, and Merck

### Paulo Fontoura
**Participation Type**: leadership
**Role in Project**: Chief Medical Officer
**Participation Period**: 2025-01-present
**Expertise**: Clinical development, medical affairs
**Biography**: Senior Vice President at Roche

### David Baker
**Participation Type**: founder
**Role in Project**: Co-founder
**Participation Period**: 2023-present
**Expertise**: Protein design, computational biology, structural biology
**Biography**: Nobel Prize winner 2024, Director of the Institute for Protein Design at University of Washington, pioneer in computational protein design

### Marc Tessier-Lavigne
**Participation Type**: leadership
**Role in Project**: CEO
**Participation Period**: 2024-04-present
**Expertise**: Neuroscience, biotechnology leadership
**Biography**: Former President of Stanford University, former Chief Scientific Officer of Genentech

### Julia Tran
**Participation Type**: leadership
**Role in Project**: Chief People Officer
**Participation Period**: 2024-present
**Expertise**: Human resources, organizational development

### Jeff Jonker
**Participation Type**: leadership
**Role in Project**: President, Chief Operating Officer
**Participation Period**: 2024-07-present
**Expertise**: Biotechnology operations, drug development
**Biography**: Previously held leadership positions at Belharra Therapeutics and NGM Biopharmaceuticals

## Links

### [Xaira Therapeutics to Expand into 73,075 Square Feet of Space in San Francisco, California](https://www.intelligence360.news/xaira-therapeutics-to-expand-into-73075-square-feet-of-space-in-san-francisco-california/)
**Type**: news_article
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-04-01
**Description**: News about office expansion plans

### [Xaira Therapeutics - Our Approach](https://www.xaira.com/our-approach)
**Type**: website
**Relevance**: primary
**Category**: source
**Description**: Company website describing Xaira's approach to AI-driven drug discovery

### [Xaira Therapeutics Announces the Appointment of Dr. Paulo Fontoura as Chief Medical Officer and Dr. Hetu Kamisetty as Chief Technology Officer](https://www.businesswire.com/news/home/20241211004372/en/Xaira-Therapeutics-Announces-the-Appointment-of-Dr.-Paulo-Fontoura-as-Chief-Medical-Officer-and-Dr.-Hetu-Kamisetty-as-Chief-Technology-Officer)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2024-12-11
**Description**: Press release announcing executive appointments and headquarters relocation

### [Xaira Therapeutics Releases 8 Million Cell Dataset, Touting It as the Largest Public Resource for AI Drug Discovery](https://www.rdworldonline.com/xaira-therapeutics-releases-8-million-cell-dataset-touting-it-as-the-largest-public-resource-for-ai-drug-discovery/)
**Type**: news_article
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-06-01
**Description**: News about X-Atlas/Orion dataset release

### [Xaira Therapeutics Appoints Biotech Exec Behind Belharra and Ambys as President and COO to Scale AI-Driven Drug Discovery Platform](https://www.biopharmatrend.com/news/xaira-therapeutics-appoints-biotech-exec-behind-belharra-and-ambys-as-president-and-coo-to-scale-ai-driven-drug-discovery-platform-1312/)
**Type**: news_article
**Relevance**: primary
**Category**: source
**Publication Date**: 2024-07-01
**Description**: News about Jeff Jonker appointment as President and COO

### [Xaira Therapeutics - Work With Us](https://www.xaira.com/work-with-us)
**Type**: website
**Relevance**: primary
**Category**: source
**Description**: Company website with office locations and career information

### [Xaira Therapeutics Launches with Over $1 Billion in Funding to Reimagine Drug Discovery and Development](https://www.businesswire.com/news/home/20240423707240/en/)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2024-04-23
**Description**: Official press release announcing Xaira Therapeutics launch and $1B+ Series A funding

### [Xaira Therapeutics Appoints Dr. Debbie Law as CSO](https://readmagazine.com/industries/biotechnology/xaira-therapeutics-appoints-dr-debbie-law-as-cso/)
**Type**: news_article
**Relevance**: primary
**Category**: source
**Publication Date**: 2024-10-01
**Description**: News about Debbie Law appointment as CSO

### [Xaira, an AI drug discovery startup, launches with a massive $1B, says it's ready to start developing drugs](https://techcrunch.com/2024/04/24/xaira-an-ai-drug-discovery-startup-launches-with-a-massive-1b-says-its-ready-to-start-developing-drugs/)
**Type**: news_article
**Relevance**: primary
**Category**: source
**Publication Date**: 2024-04-24
**Description**: TechCrunch article about Xaira launch

## Financials

### funding
**Amount**: Over $1 billion USD
**Amount (Numeric)**: 1000000000
**Funding Date**: 2024-04-01
**Source**: ARCH Venture Partners, Foresite Labs
**Funding Type**: Series A
**Description**: Series A funding round of over $1 billion to launch Xaira Therapeutics and support AI-driven drug discovery platform development
**Details**:
```yaml
lead_investors:
  - ARCH Venture Partners
  - Foresite Labs
co_incubated_by:
  - ARCH Venture Partners
  - Foresite Labs
participating_investors:
  - Foresite Capital
  - F-Prime Capital
  - NEA
  - Sequoia Capital
  - Lux Capital
  - Lightspeed Venture Partners
  - Menlo Ventures
  - Two Sigma Ventures
  - SV Angel
  - Parker Institute for Cancer Immunotherapy
```

### funding
**Amount**: Over $1 billion USD
**Amount (Numeric)**: 1000000000
**Funding Date**: 2024-04-01
**Source**: ARCH Venture Partners, Foresite Labs
**Funding Type**: Series A
**Description**: Series A funding round of over $1 billion to launch Xaira Therapeutics and support AI-driven drug discovery platform development
**Details**:
```yaml
lead_investors:
  - ARCH Venture Partners
  - Foresite Labs
co_incubated_by:
  - ARCH Venture Partners
  - Foresite Labs
participating_investors:
  - Foresite Capital
  - F-Prime Capital
  - NEA
  - Sequoia Capital
  - Lux Capital
  - Lightspeed Venture Partners
  - Menlo Ventures
  - Two Sigma Ventures
  - SV Angel
  - Parker Institute for Cancer Immunotherapy
```

## Events

### Company Founded
**Date**: 2023-01-01
**Type**: foundation
**Description**: Xaira Therapeutics founded, co-incubated by ARCH Venture Partners and Foresite Labs

### Company Founded
**Date**: 2023-01-01
**Type**: foundation
**Description**: Xaira Therapeutics founded, co-incubated by ARCH Venture Partners and Foresite Labs

### Company Launch
**Date**: 2024-04-01
**Type**: launch
**Description**: Xaira Therapeutics officially launched with over $1 billion in Series A funding. Marc Tessier-Lavigne appointed as CEO

### Company Launch
**Date**: 2024-04-01
**Type**: launch
**Description**: Xaira Therapeutics officially launched with over $1 billion in Series A funding. Marc Tessier-Lavigne appointed as CEO

### Executive Appointment
**Date**: 2024-07-01
**Type**: executive_appointment
**Description**: Jeff Jonker appointed as President and Chief Operating Officer to scale AI-driven drug discovery platform

### Executive Appointment
**Date**: 2024-07-01
**Type**: executive_appointment
**Description**: Jeff Jonker appointed as President and Chief Operating Officer to scale AI-driven drug discovery platform

### Strategic Partnership
**Date**: 2024-09-01
**Type**: partnership
**Description**: Xaira selected Oracle Cloud Infrastructure to accelerate AI-driven drug discovery initiatives

### Strategic Partnership
**Date**: 2024-09-01
**Type**: partnership
**Description**: Xaira selected Oracle Cloud Infrastructure to accelerate AI-driven drug discovery initiatives

### Executive Appointment
**Date**: 2024-10-01
**Type**: executive_appointment
**Description**: Debbie Law appointed as Chief Scientific Officer, joining from Bristol Myers Squibb, Janssen, and Merck

### Executive Appointment
**Date**: 2024-10-01
**Type**: executive_appointment
**Description**: Debbie Law appointed as Chief Scientific Officer, joining from Bristol Myers Squibb, Janssen, and Merck

### Executive Appointments & Relocation
**Date**: 2024-12-01
**Type**: executive_appointment
**Description**: Paulo Fontoura appointed as Chief Medical Officer (effective January 2025), Hetu Kamisetty appointed as Chief Technology Officer. Company relocated to new headquarters at Gateway of Pacific III campus in South San Francisco

### Executive Appointments & Relocation
**Date**: 2024-12-01
**Type**: executive_appointment
**Description**: Paulo Fontoura appointed as Chief Medical Officer (effective January 2025), Hetu Kamisetty appointed as Chief Technology Officer. Company relocated to new headquarters at Gateway of Pacific III campus in South San Francisco

### Expansion Announcement
**Date**: 2025-04-01
**Type**: expansion
**Description**: Announced plans to expand into 73,075 square feet of space in San Francisco, California, with expected completion by July 2025

### Expansion Announcement
**Date**: 2025-04-01
**Type**: expansion
**Description**: Announced plans to expand into 73,075 square feet of space in San Francisco, California, with expected completion by July 2025

### Dataset Release
**Date**: 2025-06-01
**Type**: product_release
**Description**: Released X-Atlas/Orion, the world's largest public Perturb-seq dataset containing information about 8 million cells

### Dataset Release
**Date**: 2025-06-01
**Type**: product_release
**Description**: Released X-Atlas/Orion, the world's largest public Perturb-seq dataset containing information about 8 million cells

## Partnerships

### strategic
**Date**: 2023-01-01
**Focus**: Company formation, strategic guidance
**Description**: Xaira was co-incubated by ARCH Venture Partners and Foresite Labs
**Partner Organizations**:
- Foresite Labs (partner)

### strategic
**Date**: 2023-01-01
**Focus**: Company formation, strategic guidance
**Description**: Xaira was co-incubated by ARCH Venture Partners and Foresite Labs
**Partner Organizations**:
- ARCH Venture Partners (partner)

### research
**Date**: 2024-01-01
**Focus**: Protein design research, RFdiffusion, RFantibody technologies
**Description**: Computational core based on fundamental work by co-founder David Baker and his team at the Institute for Protein Design at University of Washington
**Partner Organizations**:
- University of Washington - Institute for Protein Design (partner)

### strategic
**Date**: 2024-09-01
**Focus**: Cloud infrastructure, AI computing, drug discovery platform
**Description**: Xaira selected Oracle Cloud Infrastructure to accelerate AI-driven drug discovery initiatives
**Partner Organizations**:
- Oracle Cloud Infrastructure (partner)

### strategic
**Date**: 2023-01-01
**Focus**: Company formation, strategic guidance
**Description**: Xaira was co-incubated by ARCH Venture Partners and Foresite Labs
**Partner Organizations**:
- Foresite Labs (partner)

### strategic
**Date**: 2023-01-01
**Focus**: Company formation, strategic guidance
**Description**: Xaira was co-incubated by ARCH Venture Partners and Foresite Labs
**Partner Organizations**:
- ARCH Venture Partners (partner)

### research
**Date**: 2024-01-01
**Focus**: Protein design research, RFdiffusion, RFantibody technologies
**Description**: Computational core based on fundamental work by co-founder David Baker and his team at the Institute for Protein Design at University of Washington
**Partner Organizations**:
- University of Washington - Institute for Protein Design (partner)

### strategic
**Date**: 2024-09-01
**Focus**: Cloud infrastructure, AI computing, drug discovery platform
**Description**: Xaira selected Oracle Cloud Infrastructure to accelerate AI-driven drug discovery initiatives
**Partner Organizations**:
- Oracle Cloud Infrastructure (partner)
